Overproduction of altered VLDL in an insulin-resistance rat model: Influence of SREBP-1c and PPAR-α

Clínica e investigación en arteriosclerosis : publicación oficial de la Sociedad Española de Arteriosclerosis
D LuceroLaura Schreier

Abstract

In insulin-resistance, VLDL presents alterations that increase its atherogenic potential. The mechanism by which insulin-resistance promotes the production of altered VLDL is still not completely understood. The aim of this study was to evaluate the relationship between the expression of sterol regulatory element binding protein 1c (SREBP-1c) and of peroxisome proliferator-activated receptor-α (PPAR-α), with the features of composition and size of VLDL in an insulin-resistance rat model induced by a sucrose rich diet (SRD). The study was conducted on 12 male Wistar rats (180g) receiving SRD (12 weeks) and 12 controls. Lipid profile, free fatty acids, glucose, and insulin were measured. Lipid content in liver and visceral fat were assessed. Isolated VLDL (d<1.006g/ml) was characterized by its chemical composition and size by HPLC. The respective hepatic expression of SREBP-1c and PPAR-α was determined (Western blot). As expected, SRD had elevated triglycerides (TG), free fatty acids and insulin levels, and decreased HDL-cholesterol (p<0.05), together with augmented hepatic and visceral fat (p<0.05). SRD showed higher VLDL total mass - with increased TG content - and predominance of large VLDL (p<0.05). SRD showed an increase in ...Continue Reading

References

Nov 1, 1987·Metabolism: Clinical and Experimental·R A GutmanY B Lombardo
May 15, 1994·Genes & Development·P TontonozB M Spiegelman
Oct 26, 1999·Endocrine Reviews·B Desvergne, W Wahli
Dec 17, 2002·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·James R MeadDipak P Ramji
Dec 14, 2004·Biochimie·Delphine EberléFabienne Foufelle
Mar 28, 2008·Current Diabetes Reports·Martin AdielsJan Borén
Dec 3, 2009·American Journal of Physiology. Endocrinology and Metabolism·Gustavo J HeinRodolfo R Brenner
Mar 2, 2010·Atherosclerosis·Bruno Vergès
May 6, 2011·BMC Medicine·Eva KassiGeorge Chrousos
Jun 20, 2013·Microvascular Research·Valeria ZagoLaura Schreier

❮ Previous
Next ❯

Related Concepts

Related Feeds

Asprosin

Asprosin is a fasting-induced hormone produced in the white adipose tissue to stimulate the hepatic release of glucose into the bloodstream. Discover the latest research on this protein hormone here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.